Echocardiography in Critically-ill Patients With COVID-19 Pneumonia (ECHO-COVID)

Critical care echocardiography (CCE) has been widely used since the 10 last years. Covid outbreak leads that many patients with acute respiratory failure were admitted in the ICU. Many of these patients were ventilated and developed ARDS. Some of them developed deep vein thrombosis and pulmonary embolism. Nothing is already described about the cardiac function and the hemodynamics in these patients (how many RV failure, LV systolic dysfunction,...). The echo group of the cardiodynamix section of European society of intensive care medicien (ESICM) aims to promote CCE and evaluate its interest. The objective is to retrospectively enter in an international database all the echo studies done as usual care in these patients to evaluate (i) incidence of RV failure, (ii) incidence of LV systolic function, (iii) incidence of other patterns. Another objective will be to look for any association between some patterns and respiratory strategy, blood gas analysis, systemic hemodynamics. The echo studies were done and will be reported following one of the recent systematic review published by the same group (Huang S et al. AOIC 2020).

Study Overview

• Status: Enrolling by invitation
• Conditions: COVID; Sars-CoV2

Detailed Description

Multicenter, international observational retrospective study. Patients admitted in the ICU between March 1th and april 26th for a pneumonia related to SARS COV 2 and who had at least one echocardiography during their stay will be included. Analysis will be retrospective in order to report the hemodynamic profile with left ventricular and right ventricular function. Will be also reported the respiratory settings, the central venous presure if available as well as usual parameters of macrocirculation. All data will be reported in RedCap by the University of sydney (https://redcap.sydney.edu.au/).

• Study Type: Observational
• Enrollment (Anticipated): 1500

Contacts and Locations

Study Locations

• France
  • Hauts De Seine
    • Boulogne-Billancourt, Hauts De Seine, France, 92100
      • University Hospital Ambroise Pare

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

COVID 19 patients admitted in the ICU for respiratory failure.

Description

Inclusion Criteria: patients admitted in the ICU for pneumonia related to SARS COV2 and who had at least 1 critical care echocardiography during the first 28 days.

-

Exclusion Criteria: Patients who did not have any critical care echocardiography during the first 28 days of the ICU stay.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Left ventricular systolic dysfunction	LV systolic dysfunction is defined as an ejection fraction < 45%	Up to 28 days
Incidence of RV failure	RV failure is defined as RV/LV end-diastolic area > 0.8	up to 28 days
Incidence of Vasoplegia	Vasoplegia is defined as a normal or supranormal LV ejection fraction without echocarduiographic signs of hypovolemia.	Up to 28 days
Incidence of Hypovolemia	Hypovolemia is defined as inspiratory collaspe of the superior vena cava in ventilated patients or virtual inferior vena cava in spontaneously breathing patients.	Up to 28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Relation between plateau pressure and RV failure	Plateau pressure and RV size	Up to 28 days
Relation between tidal volume and RV failure	Tidal volume and RV size	Up to 28 days
Relation between PaO2 and RV failure	PaO2, PaO2/FiO2, and RV size	Up to 28 days
Relation between PaCO2 and RV failure	PaCO2 and RV size	Up to 28 days
Relation between PEEP and RV failure	PEEP and RV size	Up to 28 days

Collaborators and Investigators

• Sponsor: Hospital Ambroise Paré Paris
• Investigators: Principal Investigator: Antoine Vieillard-Baron, MD, PhD, Hospital Ambroise Paré Paris

Study record dates

Study Major Dates

• Study Start (Actual): May 12, 2020
• Primary Completion (Anticipated): September 30, 2021
• Study Completion (Anticipated): September 30, 2021

Study Registration Dates

• First Submitted: May 27, 2020
• First Submitted That Met QC Criteria: June 2, 2020
• First Posted (Actual): June 4, 2020

Study Record Updates

• Last Update Posted (Actual): April 29, 2021
• Last Update Submitted That Met QC Criteria: April 28, 2021
• Last Verified: April 1, 2021

More Information

Terms related to this study

• Keywords: ICU; COVID; pneumonia; critical care echocardiography
• Additional Relevant MeSH Terms: Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Lung Diseases; Pneumonia
• Other Study ID Numbers: RedCap19

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No